An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer
International Journal of Molecular Sciences · 16.01.2023 · 24 (2) · 1799
DOI: 10.3390/ijms24021799 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.01.2023. Verfasst von Domenico Tierno und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, University of Trieste, 34127 Trieste, Italy. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Cell-Free Nucleic Acids, MicroRNAs, Circulating MicroRNA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lega Italiana per la Lotta contro i Tumori, Associazione Provinciale di Trieste-Italy.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer due to its molecular heterogeneity and poor clinical outcomes. Analysis of circulating cell-free tumor nucleic acids (ctNAs) can improve our understanding of TNBC and provide efficient and non-invasive clinical biomarkers that may be representative of tumor heterogeneity. In this review, we summarize the potential of ctNAs to aid TNBC diagnosis and prognosis. For example, tumor fraction of circulating cell-free DNA (TFx) may be useful for molecular prognosis of TNBC: high TFx levels after neoadjuvant chemotherapy have been associated with shorter progression-free survival and relapse-free survival. Mutations and copy number variations of TP53 and PIK3CA/AKT genes in plasma may be important markers of TNBC onset, progression, metastasis, and for clinical follow-up. In contrast, the expression profile of circulating cell-free tumor non-coding RNAs (ctncRNAs) can be predictive of molecular subtypes of breast cancer and thus aid in the identification of TBNC. Finally, dysregulation of some circulating cell-free tumor miRNAs (miR17, miR19a, miR19b, miR25, miR93, miR105, miR199a) may have a predictive value for chemotherapy resistance. In conclusion, a growing number of efforts are highlighting the potential of ctNAs for future clinical applications in the diagnosis, prognosis, and follow-up of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
- Department of Medical and Surgical Sciences, Hospital of Cattinara, University of Trieste, 34149 Trieste, Italy.
ORCID-Profile: Domenico Tierno, Gabriele Grassi, Bruna Scaggiante
Förderung
- Lega Italiana per la Lotta contro i Tumori, Associazione Provinciale di Trieste-Italy
Zitieren
APA
Tierno, D., Grassi, G., Zanconati, F., Bortul, M., & Scaggiante, B. (2023). An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 24(2), 1799. https://doi.org/10.3390/ijms24021799
Vancouver
Tierno D, Grassi G, Zanconati F, Bortul M, Scaggiante B. An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2023;24(2):1799. doi:10.3390/ijms24021799
BibTeX
@article{Tierno2023,
author = {Tierno, Domenico and Grassi, Gabriele and Zanconati, Fabrizio and Bortul, Marina and Scaggiante, Bruna},
title = {An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {2},
pages = {1799},
doi = {10.3390/ijms24021799}
}
EUVIMED